Remember Me
Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lucas-Herald, A.; Bertelloni, S.; Juul, A.; Bryce, J.; Jiang, J.; Rodie, M.; Sinnott, R.; Boroujerdi, M.; Lindhardt-Johansen, M.; Hiort, O.; Holterhus, P.M.; Cools, M.; Guaragna-Filho, G.; Guerra-Junior, G.; Weintrob, N.; Hannema, S.; Drop, S.; Guran, T.; Darendeliler, F.; Nordenstrom, A.; Hughes, I.A.; Acerin, C.; Tadokoro-Cuccaro, R.; Ahmed, S.F. (2016)
Publisher: The Endocrine Society
Journal: The Journal of Clinical Endocrinology and Metabolism
Languages: English
Types: Article
Subjects: Original Articles
Background: In boys with suspected partial androgen insensitivity syndrome (PAIS), systematic evidence that supports the long-term prognostic value of identifying a mutation in the androgen receptor gene (AR) is lacking. Objective: To assess the clinical characteristics and long-term outcomes in young men with suspected PAIS in relation to the results of AR analysis. Methods: Through the International Disorders of Sex Development Registry, clinical information was gathered on young men suspected of having PAIS (n = 52) who presented before the age of 16 years and had genetic analysis of AR. Results: The median ages at presentation and at the time of the study were 1 month (range, 1 day to 16 years) and 22 years (range, 16 to 52 years), respectively. Of the cohort, 29 men (56%) had 20 different AR mutations reported. At diagnosis, the median external masculinization scores were 7 and 6 in cases with and without AR mutation, respectively (P = .9), and median current external masculinization scores were 9 and 10, respectively (P = .28). Thirty-five men (67%) required at least one surgical procedure, and those with a mutation were more likely to require multiple surgeries for hypospadias (P = .004). All cases with an AR mutation had gynecomastia, compared to 9% of those without an AR mutation. Of the six men who had a mastectomy, five (83%) had an AR mutation. Conclusions: Boys with genetically confirmed PAIS are likely to have a poorer clinical outcome than those with XY DSD, with normal T synthesis, and without an identifiable AR mutation. Routine genetic analysis of AR to confirm PAIS informs long-term prognosis and management.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol. 2002;16:2181-2187.
    • 2. Hiort O. The differential role of androgens in early human sex development. BMC Med. 2013;11:152.
    • 3. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995;16:271-321.
    • 4. Adachi M, Takayanagi R, Tomura A, et al. Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med. 2000; 343:856 - 862.
    • 5. Ahmed SF, Cheng A, Dovey L, et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab. 2000;85:658 - 665.
    • 6. Kalfa N, Philibert P, Werner R, et al. Minor hypospadias: the “tip of the iceberg” of the partial androgen insensitivity syndrome. PLoS One. 2013;8:e61824.
    • 7. Rodie M, McGowan R, Mayo A, et al. Factors that influence the decision to perform a karyotype in suspected disorders of sex development: lessons from the Scottish Genital Anomaly Network Register. Sex Dev. 2011;5:103-108.
    • 8. Hellmann P, Christiansen P, Johannsen TH, Main KM, Duno M, Juul A. Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Arch Dis Child. 2012;97:403- 409.
    • 9. Ahmed SF, Rodie M, Jiang J, Sinnott RO. The European Disorder of Sex Development Registry: a virtual research environment. Sex Dev. 2010;4:192-198.
    • 10. Cox K, Bryce J, Jiang J, et al. Novel associations in disorders of sex development: findings from the I-DSD Registry. J Clin Endocrinol Metab. 2014;99:E348 -E355.
    • 11. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The Androgen Receptor Gene Mutations Database (ARDB):2012 update. Hum Mutat. 2012;33:887- 894.
    • 12. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int. 2000;85:120 -124.
    • 13. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73: 1016 -1025.
    • 14. Ahmed SF, Cheng A, Hughes IA. Assessment of the gonadotrophingonadal axis in androgen insensitivity syndrome. Arch Dis Child. 1999;80:324 -329.
    • 15. Bouvattier C, Carel JC, Lecointre C, et al. Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. J Clin Endocrinol Metab. 2002;87:29 -32.
    • 16. Birnbaum W, Bertelloni S. Sex hormone replacement in disorders of sex development. Endocr Dev. 2014;27:149 -159.
    • 17. Giwercman A, Kledal T, Schwartz M, et al. Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene. J Clin Endocrinol Metab. 2000;85:2253-2259.
    • 18. Barbagli G, De Angelis M, Palminteri E, Lazzeri M. Failed hypospadias repair presenting in adults. Eur Urol. 2006;49:887- 894.
    • 19. Ashcroft GS, Mills SJ. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest. 2002;110:615- 624.
    • 20. Schneuer FJ, Holland AJ, Pereira G, Bower C, Nassar N. Prevalence, repairs and complications of hypospadias: an Australian population-based study. Arch Dis Child. 2015;100:1038 -1043.
    • 21. Jürgensen M, Kleinemeier E, Lux A, et al. Psychosexual development in adolescents and adults with disorders of sex developmentresults from the German Clinical Evaluation Study. J Sex Med. 2013; 10:2703-2714.
    • 22. Mazur T. Gender dysphoria and gender change in androgen insensitivity or micropenis. Arch Sex Behav. 2005;34:411- 421.
    • 23. Marifke J, Sandlow J. Anatomy and physiology of androgen regulation in men. Clin Urol Endocrinol. 2012;1:1-9.
    • 24. Doehnert U, Bertelloni S, Werner R, Dati E, Hiort O. Characteristic features of reproductive hormone profiles in late adolescent and adult females with complete androgen insensitivity syndrome. Sex Dev. 2015;9:69 -74.
    • 25. Pitteloud N, Dwyer AA, DeCruz S, et al. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab. 2008;93:784 -791.
    • 26. O'Hara L, Smith LB. Androgen receptor roles in spermatogenesis and infertility. Best Pract Res Clin Endocrinol Metab. 2015;29:595- 605.
    • 27. Welsh M, Moffat L, Belling K, et al. Androgen receptor signalling in peritubular myoid cells is essential for normal differentiation and function of adult Leydig cells. Int J Androl. 2012;35:25- 40.
    • 28. Deeb A, Mason C, Lee YS, Hughes IA. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome. Clin Endocrinol (Oxf). 2005;63:56 - 62.
    • 29. Bevan CL, Brown BB, Davies HR, Evans BA, Hughes IA, Patterson MN. Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndrome. Hum Mol Genet. 1996;5:265-273.
    • 30. Kyriakou A, Dessens AB, Bryce J, et al. Diagnostic approach to a newborn with suspected DSD: results from an international survey of specialist care for DSD. Horm Res Pediatr. 2015;84(supp1);P1- P61.
    • 31. Ahmed SF, Achermann JC, Arlt W, et al. Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (revised 2015). Clin Endocrinol (Oxf). 2016;84(5):771-788.
    • 32. Achermann JC, Domenice S, Bachega TA, Nishi MY, Mendonca BB. Disorders of sex development: effect of molecular diagnostics. Nat Rev Endocrinol. 2015;11:478 - 488.
    • 33. Arboleda VA, Lee H, Sánchez FJ, et al. Targeted massively parallel sequencing provides comprehensive genetic diagnosis for patients with disorders of sex development. Clin Genet. 2013;83:35- 43.
    • 34. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol. 2001;179:105-109.
    • 35. Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med. 2007;4:1056 - 1069.
    • 36. Arnhold IJ, Melo K, Costa EM, et al. 46,XY Disorders of sex development (46,XY DSD) due to androgen receptor defects: androgen insensitivity syndrome. Adv Exp Med Biol. 2011;707:59 - 61.
    • 37. Danilovic DL, Correa PH, Costa EM, Melo KF, Mendonca BB, Arnhold IJ. Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene. Osteoporos Int. 2007;18:369 -374.
    • 38. Aksglaede L, Link K, Giwercman A, Jørgensen N, Skakkebaek NE, Juul A. 47,XXY Klinefelter syndrome: clinical characteristics and age-specific recommendations for medical management. Am J Med Genet C Semin Med Genet. 2013;163C:55- 63.
    • 39. Holmboe SA, Vradi E, Jensen TK, et al. The association of reproductive hormone levels and all-cause, cancer, and cardiovascular disease mortality in men. J Clin Endocrinol Metab. 2015;100:4472- 4480.
    • 40. Tordjman KM, Yaron M, Berkovitz A, Botchan A, Sultan C, Lumbroso S. Fertility after high-dose testosterone and intracytoplasmic sperm injection in a patient with androgen insensitivity syndrome with a previously unreported androgen receptor mutation. Andrologia. 2014;46:703-706.
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • RCUK | The International DSD Netw...

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok